Zacks Investment Research downgraded Acceleron Pharma Inc (NASDAQ:XLRN) to Sell in a report released today.

Zacks Investment Research has downgraded Acceleron Pharma Inc (NASDAQ:XLRN) to Sell in a report released on Thursday October 06, 2016.

Previously on Thursday September 29, 2016, Citigroup reported about Acceleron Pharma Inc (NASDAQ:XLRN) raised the target price from $0.00 to $40.00. At the time, this indicated a possible upside of 0.01%.

Yesterday Acceleron Pharma Inc (NASDAQ:XLRN) traded -5.14% lower at $34.40. The company’s 50-day moving average is $33.69 and its 200-day moving average is $32.46. The last stock close price is up 5.84% from the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the same time. 104,994 shares of the stock were exchanged, down from an average trading volume of 260,491

See Chart Below

Acceleron Pharma Inc has a 52 week low of $21.93 and a 52 week high of $50.86 The company’s market cap is currently $0.

In addition to Zacks Investment Research reporting its target price, a total of 9 firms have reported on the stock. The consensus target price is $47.33 with 4 firms rating the stock a strong buy, 4 firms rating the stock a buy, 0 firms rating the stock a hold, 0 firms rating the stock a underperform, and finally 0 firms rating the stock a sell.

About Acceleron Pharma Inc (NASDAQ:XLRN)

Acceleron Pharma Inc. is a United States-based clinical stage biopharmaceutical company. The Company focuses on discovering and developing therapies to treat a range of diseases. Its therapeutic candidate, luspatercept, is being evaluated in Phase III studies for the treatment of the hematologic diseases myelodysplastic syndromes (MDS) and beta-thalassemia. Its Sotatercept is an investigational protein therapeutic that manages red blood cell levels by targeting molecules in the transforming growth factor beta (TGF-β) superfamily, which is being evaluated in Phase IIa studies. Its Dalantercept is an investigational protein therapeutic that inhibits angiogenesis by preventing bone morphogenetic proteins 9 (BMP) and BMP10, proteins in the TGF-β superfamily, which is being evaluated in Phase II studies. Its ACE-083 is an investigational protein therapeutic that helps to manage muscle mass and strength in specific muscles and muscle groups, which is being evaluated in Phase I studies.